Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Maximization of the anabolic effects of intermittent administration of parathyroid hormone (PTH) has recently been at the forefront of clinical research in the area of osteoporosis, with the 'anabolic window' concept as its main driving force. The outcome of these attempts, however, has not been encouraging. This article examines whether the concept itself is based on sound evidence, related pathophysiological aspects, and whether the new anti-sclerostin antibodies could have extended anabolic action.

Original publication

DOI

10.1016/j.tem.2015.01.004

Type

Journal article

Journal

Trends endocrinol metab

Publication Date

03/2015

Volume

26

Pages

111 - 113

Keywords

PTH, anabolic window, bisphosphonates, bone remodeling, denosumab, sclerostin, Anabolic Agents, Bone Density, Bone and Bones, Humans, Osteoporosis, Parathyroid Hormone